abstract |
DGAT-1 inhibitor compounds of the formula (I), acceptable salts for pharmaceutical use and prodrugs thereof, together with pharmaceutical compositions, processes for making them and their use in the treatment of, for example, obesity where, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is = O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct link or -O-; Y2 is - (CH2) r- where r is 2 or 3; n is 0 or n is 1 when Y1 is a direct link between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C) cycloalkane; Ring C is (4-6C) cycloalkane, (7-10C) bicycloalkane, (8-12C) optionally substituted tricycloalkane, phenylene or pyrdi-dindiyl; L is a direct link or -O-; p is 0, 1 or 2 and when p is 1 RA1 and RA2 are each independently hydrogen or (1-4C) alkyl; Z is car-boxi or a mimetic or a bioisoster thereof. |